Scrip
AstraZeneca's Iressa gets EU approval for subgroup of NSCLC patients
03 July 2009
Malini Guha
Please Login to read the full article.
03 July 2009
Malini Guha
malini.guha@informa.com
AstraZeneca's EGFR-targeted anticancer Iressa (gefitinib) has received approval in the EU from the
European Commission for the treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating mutations in the EGFR (epidermal growth factor receptor).This...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Nexavar fails second Phase III trial in newly diagnosed advanced lung cancer
- Experts optimistic about Pfizer's crizotinib to treat subset of lung cancer
- Pfizer faces more pressure after Sutent fails lung cancer trial
- US FDA panel rejects maintenance use of OSI/Roche's Tarceva
FEATURES
Other Informa Features
EVENTS
01 January 1970
London, UK
01 January 1970
San Diego, US
01 January 1970
Providence, Rhode Island, and San Francisco, California
JOB OF THE WEEK
Promote your vacancy here
